Kazuhiko Shien

Assistant Professor

Okayama University Hospital

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Cancer Biology Cancer Biology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Kazuhiko Shien is an Assistant Professor at Okayama University Hospital in Japan. His research primarily focuses on lung cancer, personalized medicine, and the impact of various biomarkers on treatment outcomes. Recent articles co-authored by Dr. Shien explore innovative approaches to cancer treatment, including the use of microRNA and the influence of the tumor microenvironment on chemoresistance. He is also involved in studies related to lung transplantation and therapeutic strategies for managing resistance in cancer therapies.

Articles (12)

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (9)

Masakiyo Sakaguchi

Okayama University

JAPAN

View details

Kentaro Nakata

Duke University

UNITED STATES

View details

Mikio Okazaki

Okayama University Hospital

JAPAN

View details

Akihiro Matsukawa

Okayama University

JAPAN

View details

Tomoka Takao

Senior Lecturer

Okayama Daigaku

JAPAN

View details

Haruki Choshi

Okayama University

JAPAN

View details

Haruchika Yamamoto

University Health Network

CANADA

View details

Hiromasa Yamamoto

Assistant Professor

JAPAN

View details

shuta tomida

Associate Professor

Okayama University Hospital

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kazuhiko Shien

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Long short-term memory algorithm for personalized tacrolimus dosing: A simple and effective time series forecasting approach post-lung transplantation

Adrenergic microenvironment driven by cancer‐associated Schwann cells contributes to chemoresistance in patients with lung cancer

ASO Author Reflections: Prognostic Impact of the Primary Tumor Resection for Lung Cancer Patients Diagnosed with Pleural Dissemination in the Perioperative Period—Importance of Biomarker-Based Treatment Decision Making

ASO Visual Abstract: EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery

EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery

Diagnostic value of circulating microRNA-21 in chronic lung allograft dysfunction after bilateral cadaveric and living-donor lobar lung transplantation

Functional Blockage of S100A8/A9 Ameliorates Ischemia–Reperfusion Injury in the Lung

Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer‐associated fibroblast

Robotic Mediastinal Tumor Resections: Position and Port Placement

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development

Oncogenic potential of human pluripotent stem cell‐derived lung organoids with HER2 overexpression

Protective effects of anti-HMGB1 monoclonal antibody on lung ischemia reperfusion injury in mice

Collaborators (9)

Masakiyo Sakaguchi

Kentaro Nakata

Mikio Okazaki

Akihiro Matsukawa

Tomoka Takao

Haruki Choshi

Haruchika Yamamoto

Hiromasa Yamamoto

shuta tomida

Make your next move.